Kidney Paired Donation in Live-Donor Kidney Transplantation

Bingaman, Adam W.; Wright, Francis H.; Murphey, Cathi

doi:10.1056/nejmc1004959

Cited by 45 publications

(33 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a single center KE program (San Antonio), compatible donor/ recipients pairs (where the donor was over 45 years of age and was not HLA identical) were approached for CPP (18,19). In this experience, 17 compatible pairs were included in KE procedures that provided 134 transplants.…”

Section: Cpp Clinical Experiencesmentioning

confidence: 99%

See 1 more Smart Citation

Equipoise: Ethical, Scientific, and Clinical Trial Design Considerations for Compatible Pair Participation in Kidney Exchange Programs

Cuffy

Ratner

Siegler

et al. 2015

American Journal of Transplantation

View full text Add to dashboard Cite

Section: Cpp Clinical Experiencesmentioning

confidence: 99%

“…Clinical experiences with CPP have recently accumulated (12,15,18,19). In a single center KE program (San Antonio), compatible donor/ recipients pairs (where the donor was over 45 years of age and was not HLA identical) were approached for CPP (18,19).…”

Section: Cpp Clinical Experiencesmentioning

confidence: 99%

Equipoise: Ethical, Scientific, and Clinical Trial Design Considerations for Compatible Pair Participation in Kidney Exchange Programs

Cuffy

Ratner

Siegler

et al. 2015

American Journal of Transplantation

View full text Add to dashboard Cite

“…A Cochrane database review showed that open donor nephrectomy is associated with a higher risk of DGF than laparoscopic donor nephrectomy (relative risk of 1.09, 95% CI, 0.52-2.30). 61 Interestingly, results of kidney transplant between unrelated individuals in Western countries indicate that immunologic factors such as HLA matching, ABO incompatibility, 62 and longer cold ischemia time using advanced technology such as hypothermic machine perfusion 63 have minimal effect on DGF. Therefore, further studies are certainly warranted to investigate the effect of these factors on DGF from a Middle Eastern perspective to ensure high success rate in terms of graft function.…”

Section: Other Risk Factorsmentioning

confidence: 99%

Untitled

2016

Exp Clin Transplant

View full text Add to dashboard Cite

With an increased incidence of living-donor kidney transplants, in response to increasing unmet needs for renal transplant, a clear understanding of determinants of posttransplant outcomes is essential. The importance of delayed graft function in deceased-donor kidney transplant is now part of conventional medical wisdom, due to the large amount of evidence focused on this aspect. However, the same is not true for living-donor kidney transplant, partly due to lack of evidence on this crucial clinical question and partly due to lack of awareness about this issue. The current review aims to highlight the importance of delayed graft function as a crucial determinant of outcomes in living-donor kidney transplant. An exhaustive search of online medical databases was performed with appropriate search criteria to collect evidence about delayed graft function after living-donor kidney transplant, with a special focus on studies from the Middle East. Data on incidence, impact, risk factors, and possible prevention modalities of delayed graft function in patients undergoing living-donor kidney transplant are presented. A key finding of this review is that contemporary incidence rates reported from the Middle East are comparatively higher than those reported from outside the region. Although in absolute terms the incidence is lower than deceaseddonor kidney transplant, the effects of delayed graft function on graft rejection and graft and patient survival are sufficiently large to warrant the formulation of specific treatment protocols. Key to formulating prevention and treatment strategies is identifying discrete risk factors for delayed graft function. Although this evidence is scant, an overview has been provided. Further studies examining different aspects of delayed graft function incidence after living-donor kidney transplant are urgently needed to address a so far little known clinical question.

show abstract

“…The San Antonio Hospital in Texas has a well-established paired kidney donation program that has led to 83 procedures in less than 2 years. It has been calculated that if the productivity of the San Antonio Hospital program were replicated at a national level, it would potentially result in approximately 2000 additional live donor transplantations annually [38]. Jordan et al [40] initially gave high dose IVIG (2 g/kg) treatment to XM-CDC positive recipients and the patients received a kidney transplant when their XM became negative.…”

Section: National Paired Exchange Programs In Cases Of Positive Crossmentioning

confidence: 99%

Acute Antibody-Mediated Rejection in Kidney Transplantation: Clinical and Therapeutic Aspects

E¹

2014

J Nephrol Ther

View full text Add to dashboard Cite

Acute Antibody Mediated Rejection (ABMR) in kidney transplantation is a severe complication that frequently occurs after transplantation and is due either to pre-transplant Donor-Specific Antibodies (DSAs) or to de novo DSAs. New techniques to detect DSAs in the recipient serum and advances in the assessment of graft pathology have allowed us to recognize this entity in recent years.The treatment of ABMR is a multistep process consisting of the desensitization of the patients with preformed antibodies to prevent acute ABMR: in cases of acute ABMR, the antibodies are removed from the serum and anti-B cells immunosuppressants are used.

show abstract

Kidney Paired Donation in Live-Donor Kidney Transplantation

Cited by 45 publications

References 5 publications

Equipoise: Ethical, Scientific, and Clinical Trial Design Considerations for Compatible Pair Participation in Kidney Exchange Programs

Equipoise: Ethical, Scientific, and Clinical Trial Design Considerations for Compatible Pair Participation in Kidney Exchange Programs

Untitled

Acute Antibody-Mediated Rejection in Kidney Transplantation: Clinical and Therapeutic Aspects

Contact Info

Product

Resources

About